amodio et al supplementary figure 2 042320 · amodio et al., supplementary figure 2 actin actin...

1
Amodio et al., Supplementary Figure 2 Actin Actin NCIH358 RW7213 20% FBS + - + - EGFR HER3 HER2 IP: EGFR Total Lysates NCIH358 RW7213 + - + - 20% FBS MET EGFR IP: EGFR NCIH358 C106 + - + - NCIH358 C106 + - + - Total Lysates A B Supplementary Figure 2: EGFR Immunoprecipitation (IP) assay. Western blot analysis of EGFR dimerization partners upon FBS stimulation. (A) RW7213, (B) C106. NCIH358 NSCLC cell line was included as control. Cetuximab was used to immunoprecipitate EGFR.

Upload: others

Post on 18-Oct-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Amodio et al Supplementary Figure 2 042320 · Amodio et al., Supplementary Figure 2 Actin Actin NCIH358 RW7213 20% FBS - + - + EGFR HER3 HER2 IP: EGFR Total Lysates NCIH358 RW7213-+20%

Amodio et al., Supplementary Figure 2

Actin

Actin

NC

IH35

8

RW

7213

20% FBS +- +-

EGFR

HER3

HER2

IP: EGFR

Total Lysates

NC

IH35

8

RW

7213

+- +- 20% FBS

MET

EGFR

IP: EGFR

NC

IH35

8

C10

6

+- +-

NC

IH35

8

C10

6

+- +-

Total Lysates

A B

Supplementary Figure 2: EGFR Immunoprecipitation (IP) assay. Western blot analysis of EGFR dimerization partners upon FBS stimulation. (A) RW7213, (B) C106. NCIH358 NSCLC cell line was included as control. Cetuximab was used to immunoprecipitate EGFR.